All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Novo Nordisk

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Chinaplas 2020

Participation Not Confirmed

Update your events

Novo Nordisk Reports Weight Loss of 14.9% (16.9% if taken as intended) in STEP 1 trial

Contact the Supplier

Lead Product(s): Semaglutide

Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

People treated with sc semaglutide 2.4 mg achieved a weight loss of 14.9%, from a mean baseline body weight of 105.3 kg, compared to a 2.4% weight loss with placebo. Weight loss sustained after 68 weeks of treatment, compared to 31.5% with placebo.

Novo Nordisk

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Chinaplas 2020

Participation Not Confirmed

Update your events

Novo Nordisk’s First Semaglutide Obesity Trial Hits The Mark

Contact the Supplier

Lead Product(s): Semaglutide

Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

Once-weekly semaglutide resulted in an average weight loss of 17.4% among people in a phase 3a trial, whereas those who received a dummy drug after a 20-week lead-in phase saw their body weight rebound by 6.9% during the rest 48 weeks.